Abstract Purpose of Review To discuss recent advances in the treatment of advanced
urothelial carcinoma (UC) and how best to incorporate new therapies into clinical practice …

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis
and treatment response. It consists of diverse cell types, extracellular matrix components …

Purpose: On 12 April 2019, erdafitinib gained the first FDA approval as the second-line
treatment for adult patients with locally advanced or metastatic urothelial cancer following …

Urological cancers are one of the most prevalent malignancies around the globe.
Specifically, bladder cancer severely threatens the health of humans because of its …

In the past decade, the treatment of metastatic urothelial cancer (mUC), including bladder
cancer (BC), has transformed significantly with the introduction of diverse therapies, such as …

Gemcitabine plus cisplatin (GC) combination chemotherapy is the primary treatment for
advanced bladder cancer (BC) with unresectable or metastatic disease. However, most …

In the phase II FUZE trial targeting the FGFR pathway, Debio 1347 showed limited antitumor
activity and manageable toxicity in patients with advanced solid tumors. Results from …

Increased research attention has been brought to non-enzymatic protein targeting agents as
a new and effective strategy for advancing cancer treatment. To discover this class of new …

Next-generation sequencing and excerpts from discussion in the molecular tumor board
NGS was done at the Tata Memorial Hospital, Mumbai, India, using a targeted gene panel …

An 80-year-old male was referred for an ophthalmology evaluation before starting treatment
with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib for metastatic urothelial …